A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs.

ABSTRACT:

Background

HPV testing is replacing cytology for cervical cancer screening because of greater sensitivity and superior reassurance following negative tests for the dozen HPV genotypes that cause cervical cancer. Management of women testing positive is unresolved. The need for identification of individual HPV genotypes for clinical use is debated. Also, it is unclear how long to observe persistent infections when precancer is not initially found.

Methods

In the longitudinal NCI-Kaiser Permanente Northern California Persistence and Progression (PaP) Study, we observed the clinical outcomes (clearance, progression to CIN3+, or persistence without progression) of 11,573 HPV-positive women aged 30-65 yielding 14,158 type-specific infections.

Findings

Risks of CIN3+ progres

SUBMITTER: Demarco M 

PROVIDER: S-EPMC7264956 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature